GEP PALESTINE

Obiettivi del progetto

Breast cancer (BC) is the leading cause of cancer mortality among women in the world [Torre 2017, World Health Organization 2014), accounting for 25.1% of all cancers (Ghoncheh 2016). However, its incidence in developed countries is high, while relative mortality is most considerable in less developed countries (Ghoncheh 2016). In Palestine, BC is the leading cause of cancer-related deaths among women: its mortality rate is 9.8% (Salehiniya 2016). Breast cancer among Palestinian women has lower incidence than in Europe or North America yet is very frequently familial: patients with either young onset breast cancer or a family history of breast or ovarian cancer, the proportion carrying a mutation in BRCA1 or BRCA2 was 7%, the proportion carrying TP53 p.R181C was 2%, and the proportion carrying a pathogenic mutation in any breast cancer gene was 13% (Hamameh SL 2017).

Even if there are data about genetic status of Palestinian population regarding breast cancer predisposition, no data are known about molecular classification of breast cancer. The aim of the present project is to generate preliminary data on gene expression profile of Palestinian breast cancer. We propose to perform PROSIGNA test in a significant number of “ER/PGR positive, HER2 negative” breast cancer of Palestinian patients. We will compare these results with the distribution of the molecular subtypes of breast cancer of European patients. On the basis of results obtained and further financing, we will consider to extend the enrolled patients number.

Data di inizio e fine

Responsabile del progetto

Istituzione coordinatrice del progetto

Fonte/i di finanziamento

Valore economico del progetto

60.000 euro